{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:30:50Z","timestamp":1791955850862,"version":"4.3.4"},"reference-count":34,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0502-7","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T05:04:11Z","timestamp":1549429451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury"],"prefix":"10.1136","volume":"7","author":[{"given":"Hamzah","family":"Abu-Sbeih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenglong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvi","family":"Thirumurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Dadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-6130","authenticated-orcid":false,"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"issue":"20","key":"502_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"502_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"key":"502_CR3","doi-asserted-by":"crossref","unstructured":"Kaufman Howard L., Russell Jeffery, Hamid Omid, Bhatia Shailender, Terheyden Patrick, D'Angelo Sandra P., et al., Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 2016. 17(10): p. 1374\u20131385.","DOI":"10.1016\/S1470-2045(16)30364-3"},{"issue":"1","key":"502_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"26","key":"502_CR5","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder Cancer. J Clin Oncol. 2016;34(26):3119\u201325.","journal-title":"J Clin Oncol"},{"issue":"19","key":"502_CR6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"10031","key":"502_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"E Rosenberg Jonathan","year":"2016","unstructured":"Rosenberg Jonathan E, Jean H-C, Tom P, van der Heijden Michiel S, Balar Arjun V, Andrea N, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"7","key":"502_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"Y Seiwert Tanguy","year":"2016","unstructured":"Seiwert Tanguy Y, Barbara B, Ranee M, Jared W, Raanan B, Paul EJ, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956\u201365.","journal-title":"Lancet Oncol"},{"issue":"9","key":"502_CR9","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"Y Anas","year":"2016","unstructured":"Anas Y, Armando S, Margaret S, Luigi ZP, Timmerman John M, Stephen A, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394.","journal-title":"Lancet Oncol"},{"issue":"Spec Issue","key":"502_CR10","first-page":"9","volume":"8","author":"A Andrews","year":"2015","unstructured":"Andrews A. Treating with checkpoint inhibitors-figure $1 million per patient. Am Health Drug Benefits. 2015;8(Spec Issue):9.","journal-title":"Am Health Drug Benefits"},{"key":"502_CR11","doi-asserted-by":"crossref","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. Bmj. 2018:k3529.","DOI":"10.1136\/bmj.k3529"},{"issue":"11","key":"502_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"HF Stephen","year":"2016","unstructured":"Stephen HF, Jason C, Pavlick Anna C, Caroline R, Grossmann Kenneth F, McDermott David F, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558\u201368.","journal-title":"Lancet Oncol"},{"issue":"19","key":"502_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med"},{"issue":"2","key":"502_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"key":"502_CR15","doi-asserted-by":"crossref","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95.","DOI":"10.1186\/s40425-018-0411-1"},{"key":"502_CR16","unstructured":"Abu-Sbeih Hamzah, Tang Tenglong, Ali Faisal, Johnson Daniel, Qiao Wei, Diab Adi,"},{"issue":"suppl_4","key":"502_CR17","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"CF Haanen Jbag","year":"2017","unstructured":"Haanen Jbag CF, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119\u201342.","journal-title":"Ann Oncol"},{"issue":"1","key":"502_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6(1):37.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"502_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24(8):1695\u2013705.","journal-title":"Inflamm Bowel Dis"},{"key":"502_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","volume":"99","author":"K Ikeuchi","year":"2016","unstructured":"Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report. Lung Cancer. 2016;99:148\u201350.","journal-title":"Lung Cancer"},{"key":"502_CR21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/CJI.0000000000000202","volume":"41","author":"JM Michot","year":"2018","unstructured":"Michot JM, Ragou P, Carbonnel F, Champiat S, Voisin AL, Mateus C, et al. Significance of immune-related lipase increase induced by Antiprogrammed Death-1 or death Ligand-1 antibodies: a brief communication. J Immunother. 2018;41:84\u20135.","journal-title":"J Immunother"},{"key":"502_CR22","doi-asserted-by":"publisher","first-page":"1027323","DOI":"10.1155\/2018\/1027323","volume":"2018","author":"Q Su","year":"2018","unstructured":"Su Q, Zhang XC, Zhang CG, Hou YL, Yao YX, Cao BW. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. J Immunol Res. 2018;2018:1027323.","journal-title":"J Immunol Res"},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190\u2013209.","journal-title":"Eur J Cancer"},{"issue":"1","key":"502_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31\u201341.","journal-title":"Lancet Oncol"},{"key":"502_CR25","doi-asserted-by":"crossref","unstructured":"Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with Nivolumab + Ipilimumab. J Natl Cancer Inst. 2017;109(4).","DOI":"10.1093\/jnci\/djw260"},{"issue":"17","key":"502_CR26","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Christina L, Schneider Bryan J, Atkins Michael B, Brassil Kelly J, Caterino Jeffrey M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"issue":"1","key":"502_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"5s","key":"502_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","volume":"16","author":"JA Thompson","year":"2018","unstructured":"Thompson JA. New NCCN guidelines: recognition and Management of Immunotherapy-Related Toxicity. J Natl Compr Cancer Netw. 2018;16(5s):594\u20136.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"502_CR29","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"502_CR30","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886\u201394.","journal-title":"Clin Cancer Res"},{"key":"502_CR31","doi-asserted-by":"crossref","unstructured":"Sosa A., Lopez Cadena E., Simon Olive C., Karachaliou N., Rosell R., Clinical assessment of immune-related adverse events. Ther Adv Med Oncol, 2018. 10: p. 1758835918764628.","DOI":"10.1177\/1758835918764628"},{"issue":"18","key":"502_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.clinbiochem.2017.07.003","volume":"50","author":"OZ Ismail","year":"2017","unstructured":"Ismail OZ, Bhayana V. Lipase or amylase for the diagnosis of acute pancreatitis? Clin Biochem. 2017;50(18):1275\u201380.","journal-title":"Clin Biochem"},{"key":"502_CR33","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018:Jco2017776385.","DOI":"10.1200\/JOP.18.00005"},{"issue":"1","key":"502_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.gii.2013.03.001","volume":"2","author":"S Dupuis Carolyn","year":"2013","unstructured":"Dupuis Carolyn S, Veronica B, Giles W, Karam Adib R, Anupam S, Wahid W, et al. Diagnosis and management of acute pancreatitis and its complications. Gastrointest Interv. 2013;2(1):36\u201346.","journal-title":"Gastrointest Interv"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T15:58:18Z","timestamp":1606406298000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0502-7","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"16 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective, single-center study was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study was granted waiver for consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Amir A Jazaeri received research funding from Iovance, AstraZeneca, Bristol-Myers Squibb, Pfizer, Lilly, served on Advisory Board for Iovance, Aravive, Almac, and Data Safety Monitoring Board for Genetech. Dr. Ramona Dadu received research funding from Merck, Eisai, AstraZeneca, and served on Advisory Board for Bristol-Myers Squibb. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"31"}}